These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 24590545

  • 1. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
    Miura I, Shiga T, Katsumi A, Kanno-Nozaki K, Mashiko H, Niwa S, Yabe H.
    Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
    [Abstract] [Full Text] [Related]

  • 2. Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia.
    Miura I, Takeuchi S, Katsumi A, Kanno K, Watanabe K, Mashiko H, Niwa S.
    Hum Psychopharmacol; 2012 Sep; 27(5):517-20. PubMed ID: 22927115
    [Abstract] [Full Text] [Related]

  • 3. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
    Miura I, Takeuchi S, Katsumi A, Mori A, Kanno K, Yang Q, Mashiko H, Numata Y, Niwa S.
    J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
    [Abstract] [Full Text] [Related]

  • 4. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML, Shen WW, Chen CH.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec 12; 32(8):1978-81. PubMed ID: 18848860
    [Abstract] [Full Text] [Related]

  • 5. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients.
    Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Katsuki A, Hayashi K, Atake K, Tomita M, Nakamura J.
    Hum Psychopharmacol; 2012 Jan 12; 27(1):33-8. PubMed ID: 22213405
    [Abstract] [Full Text] [Related]

  • 6. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.
    Arch Gen Psychiatry; 2003 Jul 12; 60(7):681-90. PubMed ID: 12860772
    [Abstract] [Full Text] [Related]

  • 7. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
    Kawabe K, Horiuchi F, Ueno S.
    Clin Neuropharmacol; 2013 Jul 12; 36(6):239-41. PubMed ID: 24201238
    [Abstract] [Full Text] [Related]

  • 8. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, Okugawa G, Kinoshita T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan 10; 40():110-4. PubMed ID: 23022672
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS.
    Clin Neuropharmacol; 2010 May 10; 33(3):121-5. PubMed ID: 20502130
    [Abstract] [Full Text] [Related]

  • 10. Trial of aripiprazole in the treatment of first-episode schizophrenia.
    Lee HY, Ham BJ, Kang RH, Paik JW, Hahn SW, Lee MS, Lee MS.
    Psychiatry Clin Neurosci; 2010 Feb 10; 64(1):38-43. PubMed ID: 20416024
    [Abstract] [Full Text] [Related]

  • 11. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
    Mitsonis CI, Dimopoulos NP, Mitropoulos PA, Kararizou EG, Katsa AN, Tsakiris FE, Katsanou MN.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar 30; 31(2):373-7. PubMed ID: 17092620
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Blonanserin in the treatment of schizophrenia].
    Tenjin T, Miyamoto S.
    Nihon Rinsho; 2013 Apr 30; 71(4):660-5. PubMed ID: 23678596
    [Abstract] [Full Text] [Related]

  • 14. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
    Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J.
    World J Biol Psychiatry; 2010 Mar 30; 11(2 Pt 2):256-61. PubMed ID: 20218790
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
    Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, Cho SJ, APLUS study group.
    Psychiatry Clin Neurosci; 2009 Feb 30; 63(1):73-81. PubMed ID: 19154213
    [Abstract] [Full Text] [Related]

  • 16. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I, Castro-Fornieles J, Deulofeu R, de la Serna E, Goti J, Salvà J, Bernardo M.
    Psychiatry Res; 2009 Jul 30; 168(2):110-8. PubMed ID: 19501918
    [Abstract] [Full Text] [Related]

  • 17. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
    Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R, Aripiprazole Study Group.
    J Clin Psychiatry; 2007 Feb 30; 68(2):213-23. PubMed ID: 17335319
    [Abstract] [Full Text] [Related]

  • 18. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S.
    J Affect Disord; 2009 May 30; 115(1-2):18-26. PubMed ID: 19230981
    [Abstract] [Full Text] [Related]

  • 19. Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
    Iwata N, Ishigooka J, Naoi I, Matsumoto M, Kanamori Y, Nakamura H, Higuchi T.
    CNS Drugs; 2020 Jan 30; 34(1):103-116. PubMed ID: 31883082
    [Abstract] [Full Text] [Related]

  • 20. A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder.
    Kim CY, Chung S, Lee JN, Kwon JS, Kim DH, Kim CE, Jeong B, Jeon YW, Lee MS, Jun TY, Jung HY.
    Int Clin Psychopharmacol; 2009 Jul 30; 24(4):181-8. PubMed ID: 19451828
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.